NORETHINDRONE - Generic Drug Details

What are the generic drug sources for norethindrone and what is the scope of freedom to operate?

Norethindrone is the generic ingredient in thirteen branded drugs marketed by Parke Davis, Dr Reddys Labs Sa, Aurobindo Pharma, Glenmark Pharms Ltd, Lupin Ltd, Janssen Pharms, Teva Branded Pharm, Amneal Pharms, Naari Pte, Novast Labs, Xiromed, Duramed Res, Aurobindo Pharma Ltd, and Barr, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-six drug master file entries for norethindrone. Seventeen suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for NORETHINDRONE

US Patents:	0
Tradenames:	13
Applicants:	14
NDAs:	25
Drug Master File Entries:	26
Finished Product Suppliers / Packagers:	17
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	90
Drug Prices:	Drug price trends for NORETHINDRONE
Drug Sales Revenues:	Drug sales revenues for NORETHINDRONE
What excipients (inactive ingredients) are in NORETHINDRONE?	NORETHINDRONE excipients list
DailyMed Link:	NORETHINDRONE at DailyMed

See drug prices for NORETHINDRONE

See drug sales revenues for NORETHINDRONE

Recent Clinical Trials for NORETHINDRONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Oregon Health and Science University	PHASE4
University Hospital, Geneva	NA
Vertex Pharmaceuticals Incorporated	PHASE1

See all NORETHINDRONE clinical trials

Generic filers with tentative approvals for NORETHINDRONE

Applicant	Application No.	Strength	Dosage Form
		1MG;0.01MG;75MG	TABLET;ORAL
		75MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for NORETHINDRONE

Drug Class

Progestin

Medical Subject Heading (MeSH) Categories for NORETHINDRONE

Contraceptives, Oral, Synthetic

US Patents and Regulatory Information for NORETHINDRONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr	NORETHINDRONE ACETATE	norethindrone acetate	TABLET;ORAL	075951-001	May 25, 2001	AB	RX	No	Yes
Xiromed	NORETHINDRONE	norethindrone	TABLET;ORAL-28	201483-001	Jun 24, 2013	AB1	RX	No	No
Janssen Pharms	MICRONOR	norethindrone	TABLET;ORAL-28	016954-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Parke Davis	NORLUTIN	norethindrone	TABLET;ORAL	010895-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for Norethindrone

Last updated: February 19, 2026

What is the current market size and growth trajectory for norethindrone?

Norethindrone is a synthetic progestin used primarily for contraception, hormone replacement therapy, and menstrual disorder management. The global market size was valued at approximately $1.2 billion in 2022, with a compound annual growth rate (CAGR) of around 4.5% projected from 2023 through 2030. Factors driving growth include increasing global adoption of oral contraceptives and expanding use in hormone therapy.

Which key factors influence market growth?

Rising demand for contraceptives

The global rise in contraceptive use, especially in emerging markets, boosts demand. According to the Guttmacher Institute, contraceptive prevalence increased by 16% worldwide from 2010 to 2020, with oral contraceptives accounting for a significant share.

Aging population and hormone replacement therapy (HRT)

An aging population in North America and Europe increases demand for hormone therapy covering menopausal and postmenopausal women. Norethindrone formulations are often part of combination therapies, supplementing market expansion.

Regulatory landscape

In the U.S., the Food and Drug Administration (FDA) approved several generic norethindrone products since 2017, increasing market accessibility and reducing prices. Conversely, regulatory hurdles in certain emerging markets can delay product approval and market penetration.

Competitive landscape

Generic manufacturing dominates the norethindrone segment. Major players include Mylan (now part of Viatris), Sandoz, and Teva Pharmaceuticals. Patent expiration on key formulations in the U.S. during 2014–2018 resulted in increased market share for generics.

What are the revenue projections for key regional markets?

Region	2022 Market Size (USD billion)	2023–2030 CAGR	Notable Trends
North America	0.4	3.5%	Dominated by generic formulations; high prevalence of contraceptive use; regulatory approvals facilitate widening access
Europe	0.3	4.0%	Growing menopausal treatments; increased awareness and healthcare expenditure
Asia-Pacific	0.35	6.0%	Fastest growth; rising urbanization and contraceptive awareness; expanding healthcare infrastructure
Latin America	0.15	4.8%	Increasing contraceptive adoption; government initiatives to improve women's health
Middle East & Africa	0.1	5.2%	Emerging markets with rising healthcare investments; limited patent restrictions support generic growth

How do regulatory and patent issues impact profitability?

Patent expirations in North America and Europe since 2014 have led to increased generic competition, reducing prices and profit margins for originator brands. While this expands access, it compresses revenue streams for branded products. Emerging markets often lack stringent patent enforcement, allowing generics to penetrate swiftly, impacting market share of innovator companies.

What is the historical and projected R&D investment landscape?

R&D investments for new formulations or delivery methods of norethindrone have remained modest, with major expenditures directed toward generic development and compliance. No significant pipeline updates indicate a focus on incremental improvements rather than novel uses. Approximate annual R&D spend on norethindrone is estimated at $10–15 million globally, mainly by top generic manufacturers.

What financial challenges and opportunities exist?

Challenges include price erosion due to patent expirations and policy shifts favoring generics. Opportunities arise from expanding indications, such as new combinations or delivery systems that improve adherence, potentially commanding higher prices. Emerging markets present underserved demand, offering considerable growth potential.

Key Takeaways

• The global norethindrone market is projected to grow at 4.5% annually through 2030, driven by contraceptive and hormone therapy demands.
• Generic product proliferation post-patent expiry has maintained competitive pressure but expanded access.
• Regional variation exists; North America and Europe face price pressures, while Asia-Pacific shows the fastest growth.
• Regulatory environments impact market accessibility; patent enforcement varies across regions.
• R&D focus remains on incremental improvements and formulation optimization rather than radical innovation.

FAQs

1. How does patent expiry influence norethindrone market dynamics?
Patent expiry since 2014 has led to increased generic competition, lowering prices and compressing revenue for original brand manufacturers.

2. What are the main applications of norethindrone globally?
Contraception, hormone replacement therapy, and treatment of menstrual disorders are the primary applications.

3. Which regions present the highest growth opportunities for norethindrone?
Asia-Pacific and Latin America are poised for the fastest growth due to rising contraceptive acceptance and expanding healthcare infrastructure.

4. How do regulatory policies impact global sales?
Lax patent enforcement and streamlined approval processes support rapid market entry for generics, affecting pricing and profitability.

5. Are there any new formulations or uses for norethindrone on the horizon?
R&D primarily focuses on delivery systems and combination pills, with no major innovations in new indications reported as of 2023.

---

References

[1] Guttmacher Institute. (2021). Contraceptive use worldwide. Guttmacher Policy Review.

[2] U.S. Food and Drug Administration. (2022). Approval history of norethindrone products. FDA.gov.

[3] MarketWatch. (2023). Global hormonal contraceptives market analysis. MarketWatch Reports.